Company Overview and News

 
Estrella Resources pauses trading pending nickel update from Carr Boyd

2017-10-29 proactiveinvestors.com.au
Estrella Resources Ltd has been conducting diamond drilling at the Carr Boyd Nickel Project, located 80 kilometres from Kalgoorlie in Western Australia.

 
Estrella Resources bags $1.36M for Carr Boyd Nickel Project

2017-10-23 proactiveinvestors.com.au
Estrella Resources Ltd (ASX:ESR) has successfully completed a placement to institutional and sophisticated investors to raise $1.36 million at $0.04 per share.

 
Estrella Resources eyes next steps following nickel acquisition

2017-10-18 proactiveinvestors.com.au
Estrella Resources Ltd (ASX:ESR) this week pounced on the historic Carr Boyd Nickel Project, which was mined by Great Boulder Mines and WMC in the 1970's.

 
Estrella Resources continues portfolio expansion

2017-10-10 proactiveinvestors.com.au
Estrella Resources Ltd (ASX:ESR) has been granted a trading halt by the ASX, pending details of an acquisition.

 
Estrella Resources has news pending

2017-02-24 proactiveinvestors.com.au
Estrella recently commenced reverse circulation drilling at the Mt Edwards Lithium Project, which is located in Western Australia.

 
Estrella Resources enters strategic partnership with Chinese conglomerate

2017-01-27 proactiveinvestors.com.au
The parties have agreed to establish the preliminary framework of cooperation to acquire, explore, develop and finance a mineral asset portfolio in Australia.

 
Estrella Resources awaits lithium results from Mt Edwards

2017-01-15 proactiveinvestors.com.au
The project is situated 40 kilometres south of Neometals’ (ASX:NMT) Mt Marion Lithium mine, which is currently in production.

 
Estrella Resources Ltd to reveal acquisition, raising

2016-11-01 proactiveinvestors.com.au
Estrella Resources Ltd (ASX:ESR) has an acquisition on the table, with the ASX granting the company a trading halt to prepare.

 
Quarterly Cashflow Report

2016-04-28 asx.com.au

 
Quarterly Activities Report

2016-04-28 asx.com.au

 
Change in substantial holding

2016-03-31 asx.com.au

 
Change in substantial holding

2016-03-31 asx.com.au

 
Change in substantial holding

2016-03-31 asx.com.au

 
Appendix 3B

2016-03-24 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...